Thermo Fisher Scientific Inc.

Healthcare · Medical - Diagnostics & Research

Overall research band Mixed

Quality Weak

Valuation Weak

Balance sheet Very weak

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Thermo Fisher Scientific Inc. is a global provider of scientific services, offering life sciences solutions, advanced analytical instruments, specialized diagnostic products, laboratory supplies, and biopharmaceutical services. Its main products and services include reagents, instruments, consumables, diagnostic reagent kits, blood test systems, culture media, specimen collection systems, HLA typing and testing, and laboratory equipment. The company serves a diverse customer base across pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors, as well as industrial and environmental research environments. Thermo Fisher generates revenue by selling its products and services through direct sales, customer service teams, online platforms, and third-party distributors, under recognized brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC8.7%Model input; read with the evidence status and period context.

Operating margin17.8%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years3.2%Model input; read with the evidence status and period context.

FCF margin14.9%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.